<i>In vitro</i> synergistic activity of colistin with tigecycline or β-lactam antibiotic/β-lactamase inhibitor combinations against carbapenem-resistant <i>Acinetobacter baumannii</i>

Karaoğlan, İlkay; Zer, Yasemin; Boşnak, Vuslat; Mete, Ayşe Özlem; Namıduru, Mustafa

doi:10.1177/0300060513496172

Cited by 34 publications

(25 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Another reason is to provide a synergistic effect for the salvage therapy because of the debate about low penetration of the colistin into the lungs. According to other studies, imipenem, meropenem, sulbactam, rifampicin, and tigecycline were found to have synergistic effects with colistin [2,[23][24][25][26]. Clinical studies researching the effect of combination therapy with respect to clinical response, microbiological response, and mortality have been limited, and there is no consensus.…”

Section: Discussionmentioning

confidence: 99%

Colistin alone or combined with sulbactam or carbapenem against A. baumannii in ventilator-associated pneumonia

Yilmaz

Güven

Güner

et al. 2015

J Infect Dev Ctries

View full text Add to dashboard Cite

Introduction: Colistin use has increased over the last ten years because of multidrug-resistant microorganisms. The aim of this study was to compare the clinical and microbiological efficacy of colistin alone or in combination with sulbactam or carbapenem in the treatment of ventilator-associated pneumonia (VAP) due to multidrug-resistant (MDR) and extremely drug-resistant (XDR) A. baumannii. Methodology: Cases treated for VAP because of MDR and XDR A. baumannii between January 2011 and January 2013 were included in the study. The primary and secondary outcome for colistin alone, colistin with sulbactam, and colistin with carbapenems were evaluated. The primary outcomes were clinical efficacy and microbiological efficacy; the secondary outcomes were nephrotoxicity, length of hospitalization, and mortality. Results: A total of 70 VAP patients were evaluated. A total of 17 patients (24.3%) were administered colistin alone, 20 patients (28.6%) were administered colistin and sulbactam, and 33 patients (47.1%) were administered colistin and carbapenem. Clinical and microbiological response rates were higher in the carbapenem combination group (63.6% and 63.6% in both) than in the sulbactam combination group, which registered 55.0% and 60.0%, respectively. However, this did not represent a significant difference statistically (p > 0.05). There was also no significant difference between colistin alone and the combination groups regarding clinical and microbiological efficacy and mortality. Conclusions: Neither the administration of colistin alone nor colistin combined with either sulbactam or carbapenem had any noticeable advantage in the treatment of VAP in terms of clinical response, microbiological response, nephrotoxicity, length of hospitalization, and mortality.

show abstract

Section: Discussionmentioning

confidence: 99%

Colistin alone or combined with sulbactam or carbapenem against A. baumannii in ventilator-associated pneumonia

Yilmaz

Güven

Güner

et al. 2015

J Infect Dev Ctries

View full text Add to dashboard Cite

show abstract

“…After that, strips are aseptically removed and the second strip is deposited overlapping the first one. Finally, plates are incubated for 24 hours and MIC values are recorded (Karaoglan et al, 2013) (This method is referenced in Table 1 as 1+1 strip).…”

Section: Accepted Manuscriptmentioning

confidence: 99%

“…Synergy as ∑FIC≤0.5; indifference as 4≥∑FIC>0.5 and antagonism as ∑FIC>4 (Pankey andAshcraft, 2009, Tan, Ng, Tan andHuang, 2007), or 3. Synergy as ∑FIC≤0.5; indifference as 2≥∑FIC>0.5 and antagonism as ∑FIC≥2 (Karaoglan, Zer, Bosnak, Mete and Namiduru, 2013), or 4. Synergy as ∑FIC≤0.5; additive as 1≥∑FIC>0.5; indifference as 4>∑FIC>1 and antagonism as ∑FIC≥4 (Cetin, Tekeli, Ozseven, Us and Aridogan, 2013).…”

Section: Accepted Manuscriptmentioning

confidence: 99%

A meta-analysis of in vitro antibiotic synergy against Acinetobacter baumannii

March

Bratos

2015

Journal of Microbiological Methods

View full text Add to dashboard Cite

“…The time at risk, the period of time at risk for appearance of IR-MDRAB, is a very important confounding factor to be adjusted because the probability of appearance increases with the length of time (3). The best therapeutic approach for CRAB infection is to use colistin in combination with tigecycline or cefoperazone–sulbactam or piperacillin–tazobactam (38). …”

Section: Drug Resistance Exhibited By a Baumanniimentioning

confidence: 99%

Infections Caused by Acinetobacter baumannii in Recipients of Hematopoietic Stem Cell Transplantation

Al-Anazi

Al-Jasser

2014

Front. Oncol.

View full text Add to dashboard Cite

Acinetobacter baumannii (A. baumannii) is a Gram-negative, strictly aerobic, non-fermentative coccobacillus, which is widely distributed in nature. Recently, it has emerged as a major cause of health care-associated infections (HCAIs) in addition to its capacity to cause community-acquired infections. Risk factors for A. baumannii infections and bacteremia in recipients of hematopoietic stem cell transplantation include: severe underlying illness such as hematological malignancy, prolonged use of broad-spectrum antibiotics, invasive instrumentation such as central venous catheters or endotracheal intubation, colonization of respiratory, gastrointestinal, or urinary tracts in addition to severe immunosuppression caused by using corticosteroids for treating graft versus host disease. The organism causes a wide spectrum of clinical manifestations, but serious complications such as bacteremia, septic shock, ventilator-associated pneumonia, extensive soft tissue necrosis, and rapidly progressive systemic infections that ultimately lead to multi-organ failure and death are prone to occur in severely immunocompromised hosts. The organism is usually resistant to many antimicrobials including penicillins, cephalosporins, trimethoprim–sulfamethoxazole, almost all fluoroquinolones, and most of the aminoglycosides. The recently increasing resistance to carbapenems, colistin, and polymyxins is alarming. Additionally, there are geographic variations in the resistance patterns and several globally and regionally resistant strains have already been described. Successful management of A. baumannii infections depends upon appropriate utilization of antibiotics and strict application of preventive and infection control measures. In uncomplicated infections, the use of a single active beta-lactam may be justified, while definitive treatment of complicated infections in critically ill individuals may require drug combinations such as colistin and rifampicin or colistin and carbapenem. Mortality rates in patients having bacteremia or septic shock may reach 70%. Good prognosis is associated with presence of local infection, absence of multidrug resistant strain, and presence of uncomplicated infection while poor outcome is associated with severe underlying medical illness, bacteremia, septic shock, multi-organ failure, HCAIs, admission to intensive care facilities for higher levels of care, and culture of certain aggressive genotypes of A. baumannii.

show abstract

In vitro synergistic activity of colistin with tigecycline or β-lactam antibiotic/β-lactamase inhibitor combinations against carbapenem-resistant Acinetobacter baumannii

Cited by 34 publications

References 33 publications

Colistin alone or combined with sulbactam or carbapenem against A. baumannii in ventilator-associated pneumonia

Colistin alone or combined with sulbactam or carbapenem against A. baumannii in ventilator-associated pneumonia

A meta-analysis of in vitro antibiotic synergy against Acinetobacter baumannii

Infections Caused by Acinetobacter baumannii in Recipients of Hematopoietic Stem Cell Transplantation

Contact Info

Product

Resources

About